An antibody-drug conjugate (ADC) is a newly developed, highly-targeted type of cancer therapeutic. ADCs are created by grafting monoclonal antibodies to a cytotoxic payload. This new type of cancer ...
Conjugate vaccines are composed of bacterial polysaccharide antigens covalently linked to protein carriers, enabling T cell-dependent immune responses that induce high-affinity antibodies and ...
VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug and diagnostics discovery, and Fina Biosolutions LLC (FinaBio), experts in ...
Researchers have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to preclinical results, the approach combined the benefits of ...
EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors. This is an ASCO ...
A first-in-human Phase I study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate (ADC), demonstrated manageable safety and early signs of anti-tumor activity in ...
CBX-12 targets tumor cells with exatecan, offering potential for patients ineligible for antigen-targeted therapies. Phase 2 trial evaluates CBX-12's safety, tolerability, and efficacy in ...
XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...
Bristol Myers Squibb has filled the antibody-drug conjugate (ADC) shaped hole in its pipeline by following the increasingly well-trodden path to China, handing SystImmune $800 million upfront for a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback